Efficacy and limitations of pembrolizumab for lung cancer and Hodgkin lymphoma

Zhiqian Chen

doi:10.1117/12.2669397

24 March 2023 Efficacy and limitations of pembrolizumab for lung cancer and Hodgkin lymphoma

Zhiqian Chen

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126116F (2023) https://doi.org/10.1117/12.2669397
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

Cancer, as one of the leading causes of death globally, has been widely studied by scientists for therapies against it. Chemotherapy is the treatment of cancer that has been used with a long history, but its efficacy has reached the bottleneck due to its high toxicity. The lack of targeting specificity of chemotherapy is one of the major causes of adverse effects upon its usage. Compared to chemotherapy, more targeted therapies are becoming prevalent as they provide a better safety profile. Pembrolizumab, a programmed death ligand-1 targeting drug, is a newly approved targeting medication. While displaying a high efficacy against developed lung cancer and Hodgkin lymphoma, pembrolizumab also exhibits an acceptable toxicity property. However, mutation loads and gene mutations leads to resistance of pembrolizumab treatment. This review focus on the advantage of pembrolizumab over chemotherapy, the detailed efficacy of pembrolizumab against developed lung cancer and Hodgkin lymphoma, and the specific resistance upon usage of pembrolizumab.

Citation Download Citation

Zhiqian Chen "Efficacy and limitations of pembrolizumab for lung cancer and Hodgkin lymphoma", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126116F (24 March 2023); https://doi.org/10.1117/12.2669397

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available